Clincosm LogoSign in Get a demo

Yale-HF: Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04237701
Collaborator
(none)
40,000
Enrollment
1
Location
75
Anticipated Duration (Months)
533.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    40000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Other
    Official Title:
    Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
    Actual Study Start Date :
    Oct 1, 2019
    Anticipated Primary Completion Date :
    Dec 30, 2025
    Anticipated Study Completion Date :
    Dec 30, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants hospitalized for heart failure [10 years]

      Heart Failure hospitalizations

    2. Doses of therapies that comprise guideline directed medical therapy [10 years]

      Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Seen within the Yale New Haven Health System

    • Diagnosis of heart failure

    Exclusion Criteria:
    • Age<18

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Yale New Haven Health System New Haven Connecticut United States 06510

    Sponsors and Collaborators

    • Yale University

    Investigators

    • Study Director: Nihar Desai, MD MPH, Yale University
    • Principal Investigator: Tariq Ahmad, MD MPH, Yale University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yale University
    ClinicalTrials.gov Identifier:
    NCT04237701
    Other Study ID Numbers:
    • 2000026771
    First Posted:
    Jan 23, 2020
    Last Update Posted:
    Jul 14, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Heart Failure

    Study Results

    No Results Posted as of Jul 14, 2021